A San Diego biotech is trying to turn a quietly miserable condition into its next big late-stage bet. Crystalys Therapeutics is pushing dotinurad, an oral gout drug already used in several Asian markets, toward possible U.S. approval, even though it is still investigational here and very much not a cure yet. The company is now trying to lock down the clinical data and cash it needs for a future U.S. application.
The stakes are very local. More than 100,000 San Diegans live with gout, according to The San Diego Union-Tribune. Gout flares strike when uric acid builds up and forms crystals in joints, turning them hot, swollen and painfully tender. The newspaper reported that Crystalys holds licensing rights for dotinurad across North America, Europe, the Middle East and North Africa.
Dotinurad Targets The Kidney’s Uric-Acid Pipeline
Dotinurad is designed to block URAT1, a transporter that helps the kidneys reabsorb uric acid, so more of that uric acid leaves the body through urine instead of settling into joints. Crystalys describes the pill as a once-daily, selective URAT1 inhibitor, and Crystalys Therapeutics says it is headquartered in San Diego and focused on gout therapies.
The drug does not appear out of thin air. A company release carried by PR Newswire said dotinurad already had regulatory approval in Japan, China, the Philippines and Thailand, while a later financing release also listed Taiwan. Those green lights may help explain investor and physician interest, but none of them replace a full U.S. Food and Drug Administration review.
Phase 3 Trials Will Decide Whether The Pitch Holds Up
Crystalys’ main late-stage test is RUBY, a randomized, double-blind Phase 3 trial that pits dotinurad against allopurinol in adults with gout. The ClinicalTrials.gov entry lists an estimated 500 participants and says the primary goal is driving down serum uric acid by week 24. RUBY is still recruiting and is expected to wrap up in late 2027.
The company is also running AMETHYST, a Phase 2 study aimed at patients who cannot tolerate xanthine oxidase inhibitors or who have failed uricase treatment. That trial is designed to enroll 90 adults, signaling that Crystalys is aiming beyond the narrow slice of people who have simply exhausted the usual playbook.
On July 22, Crystalys announced a $130 million Series B financing to help bankroll its global Phase 3 program and early commercialization work. The company says the development plan includes RUBY and another Phase 3 study called TOPAZ, along with the AMETHYST Phase 2 trial, according to PR Newswire.
The Current Options Come With Their Own Limits
For now, most patients start with allopurinol. It is a long-standing first-line treatment, but The San Diego Union-Tribune reported it works for only about half of them. Another drug, febuxostat, carries a boxed warning after a cardiovascular safety study found that gout patients with established heart disease had a higher rate of cardiovascular death than those taking allopurinol, according to the U.S. Food and Drug Administration.
For Crystalys CEO James Mackay, the quest is not just a business plan. He told The San Diego Union-Tribune that his father suffered from gout in silence, a memory that helped drive his push to bring a new option back to San Diego. Mackay expects topline data from the late-stage program in late 2027, though that is a forecast, not a guarantee of approval, pharmacy shelves stocked with dotinurad or a pain-free future for patients.
